ARIAD announces FDA acceptance of NDA filing for Ponatinib ARIAD Pharmaceuticals announced that the FDA has accepted for filing the New Drug Application for accelerated review of ARIAD’s investigational BCR-ABL inhibitor, ponatinib, in patients with resistant or intolerant chronic myeloid leukemia or Philadelphia-chromosome positive acute lymphoblastic leukemia. The FDA also has granted ARIAD’s request for Priority Review, which is given to investigational medicines that have the potential for providing significant improvement in the treatment, prevention, or diagnosis of a disease. The FDA has established an action date of March 27, 2013 under the Prescription Drug User Fee Act.
News For ARIA From The Last 14 Days
Check below for free stories on ARIA the last two weeks.
Subscribe for More Information